Recently, Dunwill Medical was awarded the "Original Biomarkers Development Company of the Year in Asia 2025" award, recognizing its outstanding achievements in the development and translation of original biomarkers! This award aims to honor outstanding companies in the biopharmaceutical field that drive industry progress and transformation through innovative results. Concurrently, Life Sciences Review magazine also published an in-depth feature interview with Ms. Sofia Wen, Founder and CEO of Dunwill Medical, and the company.

As an authoritative media in the life sciences and business sectors, Life Sciences Review is committed to providing communication and feature coverage of top companies in the pharmaceutical and biotechnology industries. As emphasized by Ms. Sofia Wen, Founder and CEO of Dunwill Medical, in the interview: "Our strongest R&D capability lies not just in publishing laboratory research in literature, but in translating clinicians' insights into reliable in vitro diagnostic products." Dunwill Medical's success stems from its unique dual-drive model of "Clinical Needs Leadership + Industrialization Execution," which effectively overcomes the core challenges of translating scientific research into clinical products.

Innovation Rooted in Clinical Practice 

Dunwill Medical bases its innovation on the principle of "Strong Together." Its starting point for R&D always revolves around actual clinical needs and challenges, rather than merely pursuing technological frontiers. Through deep collaboration with experts from top-tier domestic hospitals, the company accurately identifies pain points and unmet needs in the diagnosis and treatment process. It combines these issues with cutting-edge biomarker research to ensure the developed solutions are both innovative and clinically practical, effectively serving to enhance patient diagnosis and treatment levels.

Overcoming Barriers in Biomarker Translation 

In the process of biomarker translation, Dunwill Medical's core advantage lies in its full-chain industrialization capabilities. The company provides comprehensive technical support to its clinical partners, ranging from biomarker verification and process development to large-scale production. A representative achievement is the liver cancer molecular testing kit, miRNA7, developed in collaboration with Dunwill Medical based on research discoveries from Zhongshan Hospital Affiliated with Fudan University. As the first such product approved by China's NMPA, it boasts an AUC value of up to 0.941 for detecting hepatocellular carcinoma, performing particularly well in early diagnosis and detecting AFP-negative liver cancer. Since its launch, this product has completed over 5 million tests, becoming a trusted diagnostic tool in clinical practice.

Building Long-Term Partnerships 

Dunwill Medical is committed to building a long-term, win-win collaborative ecosystem. By involving clinical experts throughout the entire process from discovery to productization, it enhances their sense of participation and ownership. Simultaneously, the company offers flexible IVD platform options and, leveraging its efficient NMPA registration and approval capabilities, provides clients with end-to-end "one-stop" solutions. This significantly reduces translation risks and accelerates the marketization of innovative products.

International Standard Production System as Safeguard 

Quality is Dunwill Medical's lifeline. The company has established a full-chain quality management system compliant with ISO13485 standards, possessing GMP facilities and a CAP-accredited laboratory that meet international standards. This relentless pursuit of quality and compliance is not a constraint on innovation but rather the cornerstone for ensuring product reliability and building trust among healthcare providers and patients. It guarantees that every diagnostic product possesses a high degree of accuracy and reproducibility.

Shaping the Future of Precision Medicine 

Looking ahead, Dunwill Medical continues to invest in cutting-edge technological fields such as multi-omics, single-cell analysis, and artificial intelligence, maintaining the leading edge of its R&D pipeline. By integrating real-world data with clinical research, the company continuously optimizes its marketed products, promoting the ongoing iteration of diagnostic solutions in line with clinical needs. It is dedicated to translating scientific breakthroughs into clinical value that tangibly improves patient outcomes.

This award not only affirms Dunwill Medical's clinical-value-oriented and industrialization-capability-supported innovation model but also provides a successful paradigm for global biomarker development and translation.

Looking to the future, Dunwill Medical will remain steadfast in its mission of "Creating More Possibilities for Modern Medicine," accelerating the clinical translation and application of innovative achievements, and contributing to the high-quality development of the global biopharmaceutical industry.

Click the link to read the full interview: https://www.lifesciencesreviewapac.com/dunwill-medical